Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Up 8.9% in December

Heron Therapeutics, Inc. (NASDAQ:HRTX) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 29,980,000 shares, a growth of 8.9% from the November 30th total of 27,540,000 shares. Based on an average daily volume of 3,110,000 shares, the days-to-cover ratio is currently 9.6 days.

Institutional Investors Weigh In On Heron Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HRTX. Clearline Capital LP raised its holdings in Heron Therapeutics by 48.9% during the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock valued at $4,431,000 after buying an additional 731,246 shares during the period. Congress Park Capital LLC increased its position in Heron Therapeutics by 25.3% during the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock valued at $3,936,000 after acquiring an additional 399,577 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Heron Therapeutics by 256.2% in the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after acquiring an additional 1,266,697 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Heron Therapeutics by 1,460.9% in the 2nd quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock worth $2,125,000 after acquiring an additional 568,238 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its stake in shares of Heron Therapeutics by 18.4% during the 3rd quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company’s stock worth $1,020,000 after purchasing an additional 79,680 shares during the period. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on HRTX shares. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a report on Wednesday, December 4th.

Heron Therapeutics Stock Performance

HRTX stock opened at $1.53 on Thursday. The firm has a fifty day moving average price of $1.52 and a 200 day moving average price of $2.09. Heron Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The firm has a market cap of $232.71 million, a PE ratio of -8.50 and a beta of 1.67.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $32.81 million during the quarter, compared to analysts’ expectations of $36.40 million. During the same period in the previous year, the business earned ($0.17) earnings per share. On average, equities analysts predict that Heron Therapeutics will post -0.13 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.